Lucid Diagnostics (LUCD), a cancer prevention medical diagnostics company subsidiary of PAVmed (PAVM), announced the execution of a memorandum of understanding with Front Line Mobile Health, a comprehensive medical care provider for first responders. The MOU focuses on the exploration of co-marketing and collaboration opportunities to promote and expand patient access to Lucid’s EsoGuard Esophageal DNA test for the early detection of esophageal precancer, particularly among firefighters. Front Line is a veteran-owned company that specializes in providing comprehensive medical care for first responders, including fire, law enforcement, and emergency medical services.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics’ EsoGuard cancer diagnosis test highlighted in publication
- PAVmed Provides Business Update and Second Quarter 2024 Financial Results
- Lucid Diagnostics Unveils Key Unfiled Financial Snapshot
- Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
- Lucid Diagnostics reports Q2 EPS (20c), consensus (22c)